Reuters12h
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...
Hosted on MSN18h
Intercept loses Ocaliva FDA full approval bid in rare liver disease
On the heels of an unfavourable advisory committee (AdCom) meeting, the US Food and Drug Administration (FDA) has decided not ...
Business Insider1d
Stifel Nicolaus Keeps Their Buy Rating on OmniAb (OABI)
Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on OmniAb (OABI – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $4.49. Willey covers ...
Business Insider1d
LivaNova’s Promising OSPREY Study Results Propel Buy Rating Amid Strong OSA Market Potential
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on LIVN stock, giving a Buy rating yesterday. Anthony Petrone’s rating is based on several promising developments ...